新型口服抗凝药物在肝硬化患者中的应用

全娇; 王彤宇; 金赟; 李胜; 周宁

doi:10.12449/JCH251028

新型口服抗凝药物在肝硬化患者中的应用

DOI: 10.12449/JCH251028

全娇¹,
王彤宇¹,
金赟¹,
李胜^{1, 2},
周宁^{1, 2, , ,}

1.
甘肃中医药大学第一临床医学院，兰州 730000
2.
兰州市第一人民医院感染科，兰州 730050

基金项目:

兰州市卫生健康行业科研项目 (A2024001);

兰州市卫生健康行业科研项目 (A2024010);

甘肃省科技计划项目 (25JRRA790)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：全娇负责文献检索，文章构思并撰写论文；李胜、王彤宇、金赟参与文献检索及分析；周宁负责指导论文撰写与修改。

详细信息

通信作者:
周宁， zhouning198278@163.com （ORCID： 0000-0001-8988-2860）

计量
- 文章访问数: 73
- HTML全文浏览量: 15
- PDF下载量: 25
- 被引次数: 0
出版历程
- 收稿日期: 2025-03-26
- 录用日期: 2025-04-30
- 出版日期: 2025-10-25

Application of novel oral anticoagulants in patients with liver cirrhosis

Jiao QUAN¹,
Tongyu WANG¹,
Yun JIN¹,
Sheng LI^{1, 2},
Ning ZHOU^{1, 2
, ,
,}

1.
The First Clinical Medical College of Gansu University of Chinese Medicine，Lanzhou 730000，China
2.
Department of Infectious Diseases，Lanzhou First People’s Hospital，Lanzhou 730050，China

Research funding:

Scientific Research Project in the Health Industry of Lanzhou City (A2024001);

Scientific Research Project in the Health Industry of Lanzhou City (A2024010);

Science and Technology Planning Project in Gansu Province (25JRRA790)

More Information

Corresponding author: ZHOU Ning， zhouning198278@163.com （ORCID： 0000-0001-8988-2860）

摘要

摘要: 肝硬化是一种常见的慢性进行性肝病，患者常伴有凝血功能异常，易发生血栓和出血事件。传统抗凝治疗存在诸多局限性，新型口服抗凝药物（NOAC）的出现为肝硬化患者的抗凝治疗带来了新的选择。本文全面综述了NOAC在肝硬化患者中的应用，探讨其优势与潜在风险，分析药代动力学和药效学特点，同时结合临床研究证据，评估NOAC在肝硬化相关血栓预防和治疗中的效果及安全性，以期为临床决策提供参考。
- 肝硬化 /
- 抗凝药 /
- 药代动力学
Abstract: Liver cirrhosis is a common chronic progressive liver disease， and such patients often have coagulation disorders， which may lead to thrombotic and hemorrhagic events. While traditional anticoagulant therapies have various limitations， the emergence of novel oral anticoagulants （NOAC） provides new options for anticoagulation treatment in patients with liver cirrhosis. This article comprehensively reviews the application of NOAC in patients with liver cirrhosis， discusses their advantages and potential risks， analyzes their pharmacokinetic and pharmacodynamic characteristics， and evaluates their efficacy and safety in the prevention and treatment of cirrhosis-associated thrombosis based on clinical evidence， in order to provide a reference for clinical decision-making.
- Liver Cirrhosis /
- Anticoagulants /
- Pharmacokinetics

HTML全文

参考文献(41)

[1]	GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/S0140-6736(21)01374-X.
[2]	AGENO W, CARAMELLI B, DONADINI MP, et al. Changes in the landscape of anticoagulation: A focus on direct oral anticoagulants[J]. Lancet Haematol, 2024, 11( 12): e938- e950. DOI: 10.1016/S2352-3026(24)00281-3.
[3]	ZHU MR, HU XY, SU R, et al. Research progress of coagulation dysfunction, bleeding and thrombosis in liver cirrhosis[J]. Clin Focus, 2024, 39( 7): 658- 663. DOI: 10.3969/j.issn.1004-583X.2024.07.014. 朱萌然, 胡宵月, 苏芮, 等. 肝硬化凝血功能紊乱与出血、血栓形成的研究进展[J]. 临床荟萃, 2024, 39( 7): 658- 663. DOI: 10.3969/j.issn.1004-583X.2024.07.014.
[4]	SUN RR, HE N, ZHANG FN, et al. Re-understanding of the mechanism of coagulation disorder in liver cirrhosis[J]. J Clin Hepatol, 2024, 40( 3): 616- 620. DOI: 10.12449/JCH240330. 孙荣荣, 贺娜, 张粉娜, 等. 肝硬化凝血障碍机制的再认识[J]. 临床肝胆病杂志, 2024, 40( 3): 616- 620. DOI: 10.12449/JCH240330.
[5]	YANG HX, LI YJ, HE YL, et al. Hydrogen sulfide promotes platelet autophagy via PDGFR-α/PI3K/Akt signaling in cirrhotic thrombocytopenia[J]. J Clin Transl Hepatol, 2024, 12( 7): 625- 633. DOI: 10.14218/JCTH.2024.00101.
[6]	ZHANG Y, FANG YZ, LIU Q. Research progress on the correlation between thrombocytopenia and liver cirrhosis[J]. Guizhou Med J, 2016, 40( 12): 1322- 1324. DOI: 10.3969/j.issn.1000-744X.2016.12.040. 张玉, 方宜正, 刘琦. 血小板减少与肝硬化相关性研究进展[J]. 贵州医药, 2016, 40( 12): 1322- 1324. DOI: 10.3969/j.issn.1000-744X.2016.12.040.
[7]	LEEBEEK FWG, RIJKEN DC. The fibrinolytic status in liver diseases[J]. Semin Thromb Hemost, 2015, 41( 5): 474- 480. DOI: 10.1055/s-0035-1550437.
[8]	VAIRAPPAN B. Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress[J]. World J Hepatol, 2015, 7( 3): 443- 459. DOI: 10.4254/wjh.v7.i3.443.
[9]	MARCHIANÒ S, BIAGIOLI M, BORDONI M, et al. Defective bile acid signaling promotes vascular dysfunction, supporting a role for G-protein bile acid receptor 1/farnesoid X receptor agonism and statins in the treatment of nonalcoholic fatty liver disease[J]. J Am Heart Assoc, 2023, 12( 23): e031241. DOI: 10.1161/JAHA.123.031241.
[10]	PATEL JP, GREEN B, PATEL RK, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: A rebuttal[J]. J Thromb Haemost, 2012, 10( 3): 500- 502; author reply 502- 504. DOI: 10.1111/j.1538-7836.2011.04579.x.
[11]	CHAN N, SOBIERAJ-TEAGUE M, EIKELBOOM JW. Direct oral anticoagulants: Evidence and unresolved issues[J]. Lancet, 2020, 396( 10264): 1767- 1776. DOI: 10.1016/S0140-6736(20)32439-9.
[12]	Expert Group on the Clinical Application of Rivaroxaban in China. Chinese expert recommendations for the clinical application of Rivaroxaban: Subvolume on the prevention of stroke in non-valvular atrial fibrillation[J]. Chin J Intern Med, 2013, 52( 10): 897- 902. DOI: 10.3760/cma.j.issn.0578-1426.2013.10.031. 利伐沙班临床应用中国专家组. 利伐沙班临床应用中国专家建议——非瓣膜病心房颤动卒中预防分册[J]. 中华内科杂志, 2013, 52( 10): 897- 902. DOI: 10.3760/cma.j.issn.0578-1426.2013.10.031.
[13]	YANG H, KIM SR, SONG MJ. Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban[J]. Clin Mol Hepatol, 2016, 22( 4): 499- 502. DOI: 10.3350/cmh.2016.0016.
[14]	PRIYANKA P, KUPEC JT, KRAFFT M, et al. Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis[J]. Int J Hepatol, 2018, 2018: 8432781. DOI: 10.1155/2018/8432781.
[15]	LIU S, ZHAO DQ. Research advances in rivaroxaban in the treatment of portal vein thrombosis in liver cirrhosis[J]. J Clin Hepatol, 2023, 39( 7): 1721- 1727. DOI: 10.3969/j.issn.1001-5256.2023.07.030. 刘双, 赵东强. 利伐沙班治疗肝硬化门静脉血栓的研究进展[J]. 临床肝胆病杂志, 2023, 39( 7): 1721- 1727. DOI: 10.3969/j.issn.1001-5256.2023.07.030.
[16]	BYON W, GARONZIK S, BOYD RA, et al. Apixaban: A clinical pharmacokinetic and pharmacodynamic review[J]. Clin Pharmacokinet, 2019, 58( 10): 1265- 1279. DOI: 10.1007/s40262-019-00775-z.
[17]	DIESVELD MME, PIJNENBURG DWMJ, WEERSINK RA, et al. Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data[J]. Eur J Clin Pharmacol, 2024, 80( 6): 797- 812. DOI: 10.1007/s00228-024-03648-y.
[18]	NAYMAGON L, TREMBLAY D, ZUBIZARRETA N, et al. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis[J]. Blood Adv, 2020, 4( 4): 655- 666. DOI: 10.1182/bloodadvances.2019001310.
[19]	CALDERON MARTINEZ E, SANCHEZ CRUZ C, DIARTE ACOSTA EY, et al. Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease-a systematic review and meta-analysis[J]. J Nephrol, 2025, 38( 1): 111- 126. DOI: 10.1007/s40620-024-02130-3.
[20]	CHUN HS, CHOE AR, LEE M, et al. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis[J]. Clin Mol Hepatol, 2021, 27( 4): 535- 552. DOI: 10.3350/cmh.2021.0109.
[21]	FREUND Y, COHEN-AUBART F, BLOOM B. Acute pulmonary embolism: A review[J]. JAMA, 2022, 328( 13): 1336- 1345. DOI: 10.1001/jama.2022.16815.
[22]	CHOPARD R, ALBERTSEN IE, PIAZZA G. Diagnosis and treatment of lower extremity venous thromboembolism: A review[J]. JAMA, 2020, 324( 17): 1765- 1776. DOI: 10.1001/jama.2020.17272.
[23]	TOTH PP. Stroke prevention in patients with atrial fibrillation: Focus on new oral anticoagulants[J]. Postgrad Med, 2013, 125( 3): 155- 161. DOI: 10.3810/pgm.2013.05.2670.
[24]	KARAPEDI E, PAPADOPOULOS N, TRIFYLLI EM, et al. Anticoagulation in patients with atrial fibrillation and liver cirrhosis[J]. Ann Gastroenterol, 2022, 35( 6): 557- 567. DOI: 10.20524/aog.2022.0745.
[25]	LEE ZY, SUAH BH, TEO YH, et al. Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: A systematic review and meta-analysis[J]. Am J Cardiovasc Drugs, 2022, 22( 2): 157- 165. DOI: 10.1007/s40256-021-00482-w.
[26]	SHOAMANESH A, FIELD TS, COUTTS SB, et al. Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: Subgroup analysis of the ARTESiA randomised controlled trial[J]. Lancet Neurol, 2025, 24( 2): 140- 151. DOI: 10.1016/S1474-4422(24)00475-7.
[27]	LI Z, XU WT, WANG L, et al. Risk of bleeding in liver cirrhosis receiving direct oral anticoagulants: A systematic review and meta-analysis[J]. Thromb Haemost, 2023, 123( 11): 1072- 1088. DOI: 10.1055/s-0043-1770100.
[28]	CHEN HY, ZHAO H, LI J, et al. Safe use of non-vitamin K antagonist oral anticoagulants in patients with cirrhosis[J]. Chin J Clin Pharm, 2023, 32( 2): 155- 160. DOI: 10.19577/j.1007-4406.2023.02.015. 陈海燕, 赵晖, 李剑, 等. 非维生素K拮抗剂类口服抗凝药在肝硬化患者中的安全使用[J]. 中国临床药学杂志, 2023, 32( 2): 155- 160. DOI: 10.19577/j.1007-4406.2023.02.015.
[29]	LIAKONI E, RÄTZ BRAVO AE, TERRACCIANO L, et al. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban[J]. JAMA Intern Med, 2014, 174( 10): 1683- 1686. DOI: 10.1001/jamainternmed.2014.3912.
[30]	XU QY, CHEN G, AI SX, et al. Acute kidney injury in different anticoagulation strategies: A large-scale pharmacoepidemiologic study using real-world data[J]. Cardiovasc Drugs Ther, 2025, 39( 3): 563- 572. DOI: 10.1007/s10557-024-07558-0.
[31]	LUCÀ F, OLIVA F, ABRIGNANI MG, et al. Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios[J]. J Clin Med, 2023, 12( 18): 5955. DOI: 10.3390/jcm12-185955.
[32]	BIAN L, SHAN B, LEI QX, et al. Correlation analysis of influencing factors and parameters of thromboelastography with coagulation function and platelet index[J]. Clin J Med Offic, 2023, 51( 6): 618- 621. DOI: 10.16680/j.1671-3826.2023.06.17. 卞良, 单彪, 雷秋香, 等. 血栓弹力图检测结果影响因素及其参数与凝血功能、血小板指标相关性分析[J]. 临床军医杂志, 2023, 51( 6): 618- 621. DOI: 10.16680/j.1671-3826.2023.06.17.
[33]	WHITTON TP, HEALY WJ. Review of thromboelastography(TEG): Medical and surgical applications[J]. Ther Adv Pulm Crit Care Med, 2023, 18: 29768675231208426. DOI: 10.1177/29768675231208426.
[34]	FARAONI D, DINARDO JA. Viscoelastic hemostatic assays: Update on technology and clinical applications[J]. Am J Hematol, 2021, 96( 10): 1331- 1337. DOI: 10.1002/ajh.26285.
[35]	OLDHAM M, PALKIMAS S, HEDRICK A. Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis[J]. Ann Pharmacother, 2022, 56( 7): 782- 790. DOI: 10.1177/10600280211047433.
[36]	MENICHELLI D, RONCA V, di ROCCO A, et al. Direct oral anticoagulants and advanced liver disease: A systematic review and meta-analysis[J]. Eur J Clin Invest, 2021, 51( 3): e13397. DOI: 10.1111/eci.13397.
[37]	DE MARIA C, GALANTE A, FASOLI A, et al. When and how to use direct oral anticoagulants in patients with advanced chronic liver disease[J]. Curr Opin Pharmacol, 2021, 60: 111- 116. DOI: 10.1016/j.coph.2021.07.006.
[38]	BISWAS S, BAHAR Y, BAHAR AR, et al. Present knowledge on direct oral anticoagulant and novel oral anti coagulants and their specific antidotes: A comprehensive review article[J]. Curr Probl Cardiol, 2023, 48( 2): 101483. DOI: 10.1016/j.cpcardiol.2022.101483.
[39]	XIA YQ, HU Y, TANG L. Factor XIa inhibitors as a novel anticoagulation target: Recent clinical research advances[J]. Pharmaceuticals(Basel), 2023, 16( 6): 866. DOI: 10.3390/ph16060866.
[40]	HARRINGTON J, PICCINI JP, ALEXANDER JH, et al. Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week[J]. J Am Coll Cardiol, 2023, 81( 8): 771- 779. DOI: 10.1016/j.jacc.2022.11.057.
[41]	CHAN N, CARLIN S, HIRSH J. Anticoagulants: From chance discovery to structure-based design[J]. Pharmacol Rev, 2025, 77( 2): 100037. DOI: 10.1016/j.pharmr.2025.100037.